Both in vitro and in vivo findings have shown suppressed Rac1-dependent efficacies, microfilament depolymerization, and cell motility, thereby suggesting melittin as an excellent therapeutic candidate for HCC via suppression of the Rac1-dependent pathway [26]. The gene discussed is RAC1; the disease is hepatocellular carcinoma.